Please assess the completion status of the following clinical trial:

Trial Title: Fat Malabsorption in Chronic Pancreatitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (CP):~* Chronic pancreatitis diagnosis by gastroenterologist. Participants with CP will be characterized based on the TIGAR-O (toxic, genetic, autoimmune, recurrent, obstructive) etiology system, on pancreatic morphology (Cambridge criteria) when available, and on physiological state (exocrine and endocrine function) as recommended by the recent American Pancreatic Association Practice Guidelines4.~* Age 30-70 years old~* Evidence of at-risk for malabsorption including: 1) history of use of and response to pancreatic enzyme medication; 2) history of unintentional weight loss; 3) history of increased stools per week or fatty stools; and/or 4) other clinical signs or symptoms suggestive of fat malabsorption~* In usual state of health for past two weeks including no change in medications~* Able to consume a moderate fat diet for stool evaluations~* Able to participate in the study for about four weeks with two study visits~Inclusion Criteria (Healthy Volunteers):~* Age 30-70 years old~* No known chronic disease that would affect dietary intake or fat absorption~* In usual state of health for past two weeks, with stable medications, diet and weight~* BMI from 18-29~* Able to consume a moderate fat diet for stool evaluations~* Able to participate in the study for about one week with one study visit~Exclusion Criteria (CP):~* Evidence of normal fat absorption in medical record~* Medications that alter fat absorption (i.e. orlistat, other weight loss medications, ursodeoxycholic acid)~* Allergy to pork products~* History of intestinal blockage or fibrosing colonopathy~* History of gout, kidney disease, or high blood uric acid (hyperuricemia)~* Pregnancy or breast feeding~Exclusion Criteria (Healthy Volunteers):~* Evidence of fat malabsorption~* Medications that alter fat absorption (i.e. orlistat, other weight loss medications, ursodeoxycholic acid)~* Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Chronic Pancreatitis (CP) Subjects (Type: EXPERIMENTAL): CP subjects will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary.~Subjects will take Creon36™ for 9 days.~Subjects will have two study visits, one before and one after treatment initiation with Creon36™. Both visits will be identical with the exception of completion of questionnaires and fecal elastase assessment (only Visit 1).
- Healthy Controls (Type: NO_INTERVENTION): Healthy controls will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary. Controls will only have 1 study visit and receive no intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).